ANI Pharmaceuticals
ANIP
Market cap $1.26B

60.12 USD

+0.46

0.77%

At close Oct 17, 4:00 PM EDT

After hours

60.12

+0.00

0.00%

1 day

0.77%

5 days

7.17%

1 month

0.10%

3 months

-4.54%

6 months

-8.19%

Year to date

5.12%

1 year

3.02%

5 years

-18.08%

About: ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Employees: 642

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

459% more call options, than puts

Call options by funds: $3.16M | Put options by funds: $566K

17% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 63

3.98% more ownership

Funds ownership: 68.17% [Q1] → 72.16% (+3.98%) [Q2]

3% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 31

1% more funds holding

Funds holding: 200 [Q1] → 201 (+1) [Q2]

3% less capital invested

Capital invested by funds: $992M [Q1] → $963M (-$29M) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$60

0%

upside

Avg. target

$80

33%

upside

High target

$94

56%

upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

Piper Sandler David Amsellem 65% 1-year accuracy 24 / 37 met price target	13%upside $68	Overweight Initiated	11 Oct 2024
Raymond James Elliot Wilbur 100% 1-year accuracy 2 / 2 met price target	38%upside $83	Outperform Maintained	18 Sept 2024
HC Wainwright & Co. Oren Livnat 57% 1-year accuracy 13 / 23 met price target	56%upside $94	Buy Reiterated	17 Sept 2024
Truist Securities Gregory Fraser 20% 1-year accuracy 1 / 5 met price target	0%downside $60	Hold Downgraded	11 Sept 2024
HC Wainwright & Co. Oren Livnat 57% 1-year accuracy 13 / 23 met price target	56%upside $94	Buy Reiterated	7 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about ANIP published over the past 30 days

Zacks Investment Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks Investment Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks Investment Research

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?

ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential

Piper Sandler has initiated coverage on ANI Pharmaceuticals ANIP, an integrated specialty pharmaceutical firm that develops and markets branded and generic medicines.

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

Today, we revisit small biopharma ANI Pharmaceuticals, as it is a GARP stock trading near technical support, with solid growth prospects. The company recently acquired Alimera Sciences for $380 million, boosting its rare disease segment with a couple of durable ophthalmology products. Analyst firms are generally bullish on the company's prospects and the stock trades at 12 times trailing earnings, despite revenue growth in the high teens.

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

Zacks Investment Research

Wall Street Analysts Predict a 42.98% Upside in ANI (ANIP): Here's What You Should Know

The consensus price target hints at a 43% upside potential for ANI (ANIP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 42.98% Upside in ANI (ANIP): Here's What You Should Know

Zacks Investment Research

Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?

ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2%

PRINCETON, N.J., Sept. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Ketoconazole Shampoo, 2%. ANI's Ketoconazole Shampoo, 2% is the generic version of the reference listed drug (RLD) Nizoral®.

ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2%

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced the completion of its previously announced acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”).

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM).

ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

See News Rankings

Charts implemented using Lightweight Charts™